Follow the connections. Inspect every edge.

Current U.S. guideline recommendation and implementation context.

Independent international recommendations support broad antimalarial use.

Recommends minimizing glucocorticoid exposure and earlier steroid-sparing treatment.

Provides an independent treat-to-target and tapering framework.

Organ-specific recommendations and shared decision-making framework.

Kidney-specific treatment and monitoring context.

Primary U.S. label for indication, population, administration, warnings, and adverse reactions.

Five-person compassionate-use SLE series reported drug-free remission during reported follow-up.

All eight SLE participants in the 15-person autoimmune series met DORIS remission in the reported follow-up.

Defines what DORIS remission does and does not mean.

Reported B-cell depletion followed by reconstitution with naive phenotypes in the small SLE cohort.

Follow-up supports a reconstitution pattern but remains too short and small to establish permanent tolerance.

Primary safety observations from 15 autoimmune-disease participants.

Ongoing follow-up specifically measures adverse events for up to two years.

The report had no rituximab control arm.

The follow-up series had no comparative treatment arm.

The phase 2 study is open-label rather than a rituximab comparison.

Registered phase 1/2 lupus-nephritis study.

Registered phase 1/2 severe refractory SLE study.

Registered phase 2 active SLE study.

Found significant associations for some EBV antibody markers and explicitly reported marker-specific null findings and possible publication bias.

Primary human single-cell and functional study of EBV-positive B cells in SLE.

Earlier epidemiology supports association but not necessity or sufficiency.

Reported publication bias concerns, methodological limitations, and a null association for anti-EBNA1 IgG.

Provides a mechanism but is not a prospective causal or prevention study.

Supplies biological rationale for prevention research, not prevention efficacy.

Association is insufficient to estimate a vaccine prevention effect.

Identifies a plausible CD19-positive EBV reservoir.

Reports remission but does not test EBV clearance as a mediator.

Pooled 11 case-control studies and reported lower diversity/richness measures in SLE.

Primary human observational study with validation across cohorts.

Primary single-arm pilot and source of the 42.12% week-12 SRI-4 figure.

Defines the SRI composite and why it is not remission.

Primary germ-free mouse transfer experiment.

Human studies establish association and identify medication effects, not necessity.

Preclinical transfer shows modification of immune features, not a universal human initiating mechanism.

FMT pilot did not involve CAR-T.

CAR-T case series did not include microbiome intervention.

Primary human discovery study of the peripheral-blood interferon-inducible signature.

Prespecified IFN-high and IFN-low strata show that active SLE is not uniformly signature-high.

Positive prespecified BICLA primary endpoint in TULIP-2.

TULIP-1 did not meet its prespecified SRI-4 primary endpoint and bounds any claim of uniform phase 3 efficacy.

Observed responses in the IFN-low stratum contradict a simple claim that only IFN-high participants can respond, although the low subgroup was small.

The IFN-high subgroup did not meet the prespecified SRI-4 secondary endpoint in TULIP-1.

The discovery study established association, not prospective treatment-selection performance.

Current primary U.S. source for indication, limitations of use, and warnings.

Trial report documents the higher herpes-zoster frequency and studied population underlying part of the label evidence.

Demonstrates common but non-universal, treatment-sensitive BLyS dysregulation and imperfect within-person activity tracking.

Supports a longitudinal population-level relationship between plasma BLyS and later disease activity.

Clinical benefit from ligand inhibition supports pathway relevance but cannot validate circulating BAFF as an individual biomarker.

Primary phase 3 source for randomized SRI response and safety results.

Defines the current U.S. indication and safety boundaries; it does not imply universal response.

Heterogeneous BAFF biology cautions against inferring that the pathway is equally dominant in all SLE.

Primary randomized source for the 104-week renal response results.

Current U.S. indication includes active lupus nephritis receiving standard therapy.

Places BAFF inhibition within organ-specific, combination treatment and monitoring rather than as a stand-alone cure.

Primary regulatory description of belimumab's soluble-BLyS binding mechanism.

Clinical trial tests BAFF inhibition, not a B-cell-depleting product.

CAR-T directly targets CD19-positive cells after lymphodepletion, contradicting mechanistic equivalence with soluble-ligand inhibition.